Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 52004XC1126(01)

    Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 October 2004 to 15 November 2004 (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)

    JO C 289, 26.11.2004, p. 7–9 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)

    26.11.2004   

    EN

    Official Journal of the European Union

    C 289/7


    Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 October 2004 to 15 November 2004

    (Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) (1)

    (2004/C 289/07)

    Issuing of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93) — Accepted

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    22.10.2004

    EMSELEX

    Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

    EU/1/04/294/001-012

    26.10.2004

    22.10.2004

    Mimpara

    Amgen Europe BV, Minervum 7061, 4817 ZK Breda, The Netherlands

    EU/1/04/292/001-012

    26.10.2004

    22.10.2004

    Parareg

    Amgen Europe BV, Minervum 7061, 4817 ZK Breda, The Netherlands

    EU/1/04/293/001-012

    26.10.2004

    Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93) — Accepted

    Date of the decision

    Name of the medicinal product

    Holder of the marketing authorisation

    Number of the entry in the Community Register

    Date of notification

    20.10.2004

    Zeffix

    Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

    EU/1/99/114/001-003

    22.10.2004

    20.10.2004

    Puregon

    Organon NV, PO box 20, 5340 BH Oss, The Netherlands

    EU/1/96/008/038-039

    22.10.2004

    20.10.2004

    Viracept

    Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

    EU/1/97/054/001

    EU/1/97/054/003-006

    22.10.2004

    20.10.2004

    Taxotere

    Aventis Pharma SA, 20 avenue Raymond Aron, F-92165 Antony Cedex,

    EU/1/95/002/001-002

    22.10.2004

    20.10.2004

    ViraferonPeg

    Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels

    EU/1/00/132/001-050

    22.10.2004

    20.10.2004

    PegIntron

    Schering Plough Europe, Rue de Stalle, 73, B-1180 BrusselsStallestraat, 73, B-1180 Brussel

    EU/1/00/131/001-050

    22.10.2004

    22.10.2004

    Herceptin

    Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

    EU/1/00/145/001

    26.10.2004

    22.10.2004

    EMEND

    Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

    EU/1/03/262/001-006

    26.10.2004

    22.10.2004

    Sifrol

    Boehringer Ingelheim International GmbH, Binger Strasse 173 D-55216 Ingelheim am Rhein

    EU/1/97/050/001-006

    EU/1/97/050/009-012

    26.10.2004

    22.10.2004

    Bondronat

    Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

    EU/1/96/012/001-013

    26.10.2004

    28.10.2004

    Agenerase

    Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

    EU/1/00/148/001-004

    1.11.2004

    28.10.2004

    Paxene

    Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom

    EU/1/99/113/001-004

    1.11.2004

    28.10.2004

    Cancidas

    Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom

    EU/1/01/196/001-003

    1.11.2004

    28.10.2004

    Ziagen

    Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

    EU/1/99/112/001-002

    1.11.2004

    28.10.2004

    Ziagen

    Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom

    EU/1/99/112/001-002

    1.11.2004

    28.10.2004

    Ytracis

    CIS bio international, Boite postale 32, F-91192 Gif-sur-Yvette

    EU/1/03/250/001

    3.11.2004

    28.10.2004

    Mirapexin

    Boehringer Ingelheim International GmbH, Binder Strasse 173, D-55216 Ingelheim am Rhein

    EU/1/97/051/001-006

    EU/1/97/051/009-012

    1.11.2004

    28.10.2004

    Viraferon

    Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels

    Stallestraat, 73, B-1180 Brussel

    EU/1/99/128/001-008

    1.11.2004

    28.10.2004

    CoAprovel

    Sanofi Pharma Bristol-Myers Squibb SNC, 174 avenue de France, F-75013 Paris

    EU/1/98/086/001-020

    2.11.2004

    28.10.2004

    Karvezide

    Bristol-Myers Squibb Pharma EEIG, 141-149 Staines Road, Hounslow TW3 3JA, United Kingdom

    EU/1/98/085/001-020

    1.11.2004

    28.10.2004

    Viread

    Gilead Sciences International Limited, Cambridge CB1 6GT United Kingdom

    EU/1/01/200/001

    1.11.2004

    28.10.2004

    Ammonaps

    Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense

    EU/1/99/120/001-004

    2.11.2004

    28.10.2004

    IntronA

    Schering Plough Europe, Rue de Stalle, 73, B-1180 Brussels

    Stallestraat, 73, B-1180 Brussel

    EU/1/99/127/001-010

    EU/1/99/127/040

    2.11.2004

    29.10.2004

    PEGASYS

    Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom

    EU/1/02/221/001-010

    5.11.2004

    29.10.2004

    MabCampath

    ILEX Pharmaceutical Ltd, 1 & 3 Frederick Sanger Road, The Surrey Research Park, Guildford, Surrey GU2 7YD, United Kingdom

    EU/1/01/193/002

    5.11.2004

    29.10.2004

    Liprolog

    Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands

    EU/1/01/195/001-015

    5.11.2004

    4.11.2004

    Zometa

    Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom

    EU/1/01/176/001-006

    8.11.2004

    4.11.2004

    Zyprexa

    Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands

    EU/1/96/022/002, EU/1/96/022/004, EU/1/96/022/006, EU/1/96/022/008-012, EU/1/96/022/014, EU/1/96/022/016-022

    8.11.2004

    4.11.2004

    Zyprexa Velotab

    Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands

    EU/1/99/125/001-008

    8.11.2004

    4.11.2004

    Zyprexa Velotab

    Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, The Netherlands

    EU/1/99/125/001-008

    8.11.2004

    9.11.2004

    Vfend

    Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom

    EU/1/02/212/001-026

    15.11.2004

    12.11.2004

    Arixtra

    Sanofi-Synthelabo 174 avenue de France, F-75013 Paris

    EU/1/02/206/009-017

    16.11.2004

    12.11.2004

    Quixidar

    N.V. Organon PO box 20, Kloosterstraat 6, 5340 EB Oss, The Netherlands

    EU/1/02/207/009-017

    16.11.2004


    (1)  OJ L 214, 24.8.1993, p. 1.


    Top